Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Sweden
In shortEgetis Therapeutics AB (publ) is loss-making, burns cash and holds more cash than debt, with revenue shrinking (−20.0% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -714.5% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -745.3% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -66.2% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -42.9% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.86× | 88/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.23× | 98/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -12.72× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -6.23 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -494.4% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 4 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 4 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 3 | 0/100 |
| Revenue growth volatility | 107.5% | 0/100 |
| Operating margin volatility | 255.1% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 6.5% | 53/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 4 fiscal years from the company's annual reports.
SEK millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|
| Revenue | 38 | 23 | 58 | 46 |
| Cost of revenue | 7.9 | 6.3 | 11 | 12 |
| Gross profit | 30 | 16 | 47 | 35 |
| Research & development | – | – | 194 | 146 |
| Operating income | (106) | (198) | (325) | (329) |
| Interest expense | 0.2 | 0.7 | 4.2 | 26 |
| Pre-tax income | (105) | (194) | (327) | (343) |
| Income tax | 0 | 0 | 0.1 | 0.3 |
| Net income | (105) | (194) | (327) | (344) |
| Diluted EPS | −kr0.60 | −kr1.00 | −kr1.30 | −kr1.10 |
| Diluted shares (millions) | – | – | 260 | 311 |
−6.23 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
2/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2024 · Data updated Dec 31, 2024